Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Axogen (NASDAQ:AXGN) Jumps 20% Premarket on Q3 Beat, Raised Guidance and Prostate Market Plans

Axogen (NASDAQ:AXGN) shares are indicated up 19.83% at $44.89 in premarket after third-quarter results topped expectations and management raised its 2026 outlook. Revenue of $75.8 million, up 26.2% from $60.1 million, beat the roughly $73.2 million consensus, and adjusted EPS of $0.21 beat the …

Nitish Kishor | 28 October 2026

Boston Scientific (NYSE:BSX) Sinks 6% Premarket as Lowered 2026 Outlook Overshadows In-Line Q3

Boston Scientific (NYSE:BSX) shares are indicated down 6.08% at $42.32 in premarket after third-quarter results that were roughly in line but a cut to the 2026 outlook as the August cyberattack weighs on the business. Revenue of $5.14 billion was up 1.5%, and adjusted …

Nitish Kishor | 28 October 2026

Penny Stock Cardiff Oncology (NASDAQ:CRDF) Edges Up 2% Premarket as Leila Alland Joins as Interim Chief Medical Officer

Cardiff Oncology (NASDAQ:CRDF) shares are indicated up 2.23% at $0.89 in premarket after the company appointed Leila Alland, MD, as interim Chief Medical Officer. She succeeds Roger Sidhu, MD, who stepped down. The stock closed Tuesday up 8.80% at $0.88.

Nitish Kishor | 28 October 2026

Penny Stock Cellectis (NASDAQ:CLLS) Rises 6% Premarket on Preclinical Data Showing 70% APOC3 Editing

Cellectis (NASDAQ:CLLS) shares are indicated up 5.71% at $1.11 in premarket after the company presented expanded preclinical data for .HEAL-101, its in vivo base editing candidate targeting APOC3 for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress. The stock closed …

Nitish Kishor | 28 October 2026

Dyne Therapeutics (NASDAQ:DYN) Slips 4% Premarket as Oppenheimer Downgrade Cuts Target to $15

Dyne Therapeutics (NASDAQ:DYN) shares are indicated down 4.19% at $16.23 in premarket after Oppenheimer downgraded the stock to Perform from Outperform and cut its price target to $15 from $40. Uncertainty around vHOT is the main focus for investors, even though the stock jumped …

Nitish Kishor | 28 October 2026

GE HealthCare (NASDAQ:GEHC) Climbs 7% Premarket as Q3 Beat and Higher 2026 Guidance Top Expectations

GE HealthCare (NASDAQ:GEHC) shares are indicated up 7.09% at $76.15 in premarket after third-quarter results topped expectations and the company raised its 2026 outlook. Adjusted EPS of $1.34, up 25.1%, beat the $1.20 consensus, and revenue of $5.5 billion, up 7.2% with organic growth …

Nitish Kishor | 28 October 2026

Penny Stock INVO Fertility (NASDAQ:IVF) Edges Higher Premarket Ahead of 1-for-4 Reverse Stock Split

INVO Fertility (NASDAQ:IVF) shares are indicated up 1.12% at $0.62 in premarket after the company announced a 1-for-4 reverse split of its issued and outstanding and authorized common stock, effective October 30. Shares will begin trading on a split-adjusted basis on the Nasdaq Capital …

Nitish Kishor | 28 October 2026

Rapport Therapeutics (NASDAQ:RAPP) Plunges 22% Premarket as It Prices Offerings at $21 a Share

Rapport Therapeutics (NASDAQ:RAPP) shares are indicated down 22.21% at $21.42 in premarket after the company priced underwritten offerings of its common stock and convertible notes. The common stock offering of about $200 million, including about $25 million of pre-funded warrants in lieu of shares, …

Nitish Kishor | 28 October 2026

Universal Health Services (NYSE:UHS) Slides 5% Premarket as Narrower Margins and a Litigation Reserve Cloud Q3

Universal Health Services (NYSE:UHS) shares are indicated down 5.12% at $168.25 in premarket after third-quarter results that were mixed. Revenue of $4.73 billion, up 5.3%, and adjusted EPS of $5.22 were roughly in line with consensus of $5.15 to $5.31, but adjusted EBITDA of …

Nitish Kishor | 28 October 2026

Absci (NASDAQ: ABSI) Stock In Play Today: Second Quarter Net Loss of $33,210 Thousand and $201.1 Million in Cash and Securities

Absci Corporation (NASDAQ: ABSI) shares were trading at USD 10.51 on October 27, 2026, up 11.16%, with a relative volume at time of 2.01. The clinical-stage biopharmaceutical company announced interim Phase 1 data from its HEADLINE trial in June 2026, completed a public offering …

Nitish Kishor | 27 October 2026
Support

Hi! How can we help you today?

Loading…